Entity

Time filter

Source Type

Valencia de Alcántara, Spain

San Juan F.,Hospital Universitario La Paz | San Juan F.,Hospital Universitario La Fe Of Valencia | Cortes M.,Hospital Universitario La Paz
Transplantation Proceedings | Year: 2011

The excellent outcomes of liver transplantation (OLT) have increased its demand and the size of the waiting list, resulting in a substantial mortality rate before OLT, which is a treatment failure owing to disease development. We have reviewed the medical literature on this theme, focusing on prioritization methods. © 2011 Elsevier Inc. All rights reserved. Source


Gil M.J.,Institute Catala dOncologia IDIBELL | De Las Penas R.,Consorcio Hospitalario Provincial de Castellon | Reynes G.,Hospital Universitario La Fe Of Valencia | Balana C.,Institute Catala dOncologia | And 11 more authors.
Anti-Cancer Drugs | Year: 2012

There is no 'standard of care' for recurrent malignant glioma (MG). Our aim is to confirm the efficacy and safety of bevacizumab 10 mg/kg plus irinotecan 125 mg/m (or 340 mg/m if enzyme-inducing antiepileptic drugs) every 2 weeks for a maximum of 1 year in a retrospective pooled series of patients with recurrent MG. The inclusion criteria were as follows: age 18 years and above, histology of MG, progression after radiation and temozolomide, Karnofsky performance status (KPS) of at least 60, and signed informed consent for bevacizumab compassionate use. Response was assessed by MRI using the Macdonald criteria and evaluation of the FLAIR sequence every 8 weeks. A total of 130 patients were enrolled; 72% had glioblastoma (GBM). The median age of the patients was 53 years (20-78); the median KPS was 80%; the median number of prior chemotherapy lines was 2 (1-5); the median interval between the diagnosis of MG and inclusion was 14.6 months (2-166); and the median number of bevacizumab infusions was 8 (1-39). The median follow-up duration was 7.2 months (1-47). The median overall survival (OS) was 8.8 months for GBM and 11.2 months for anaplastic glioma (AG). The median progression-free survival was 5.1 months for GBM and 4.6 months for AG. The response rate was 56% for GBM and 68% for AG. Neurological and KPS improvements were observed in 49 and 45% of patients. Only KPS less than 80% was associated with a worse significant response rate (odds ratio, 0.57; 95% confidence interval, 0.22-0.96). The most frequent grades 3-4 toxicities were asthenia (7%), diarrhea (6%), and thromboembolic events (5%). There were five toxic deaths (4%). Bevacizumab plus irinotecan in recurrent MG improves responses, progression-free survival, and OS compared with historical data. KPS of at least 80% was a predictive factor for response and OS. © 2012 Wolters Kluwer Health | Lippincott Williams &Wilkins. Source


Ye-Lin Y.,Polytechnic University of Valencia | Garcia-Casado J.,Polytechnic University of Valencia | Martinez-De-Juan J.L.,Polytechnic University of Valencia | Prats-Boluda G.,Polytechnic University of Valencia | Ponce J.L.,Hospital Universitario La Fe Of Valencia
Physics in Medicine and Biology | Year: 2010

Myoelectrical recording could provide an alternative technique for assessing intestinal motility, which is a topic of great interest in gastroenterology since many gastrointestinal disorders are associated with intestinal dysmotility. The pacemaker activity (slow wave, SW) of the electroenterogram (EEnG) has been detected in abdominal surface recordings, although the activity related to bowel contractions (spike bursts, SB) has to date only been detected in experimental models with artificially favored electrical conductivity. The aim of the present work was to assess the possibility of detecting SB activity in abdominal surface recordings under physiological conditions. For this purpose, 11 recording sessions of simultaneous internal and external myolectrical signals were conducted on conscious dogs. Signal analysis was carried out in the spectral domain. The results show that in periods of intestinal contractile activity, high-frequency components of EEnG signals can be detected on the abdominal surface in addition to SW activity. The energy between 2 and 20 Hz of the surface myoelectrical recording presented good correlation with the internal intestinal motility index (0.64 0.10 for channel 1 and 0.57 0.11 for channel 2). This suggests that SB activity can also be detected in canine surface EEnG recording. © 2010 Institute of Physics and Engineering in Medicine. Source


Disdier C.,CIBER ISCIII | Perez-Negrin L.,Hospital Universitario Nuestra Senora Of Candelaria | Morales P.,Hospital Universitario La Fe Of Valencia | Cordovilla R.,Hospital Universitario Of Salamanca
Archivos de Bronconeumologia | Year: 2010

Endobronchial ultrasound bronchoscopy has been one of the most important contributions to the minimally invasive diagnosis and staging of mediastinal disease in the last few years. Two original works with linear and radial endobronchial ultrasound bronchoscopy published in the Archivos de Bronconeumología are analysed. In pleural pathology, we have selected a multicentre study one the usefulness of an outpatient tunnelised pleural drainage in 63 patients with malignant neoplastic effusions. This technique was indicated in 20% when pleurodesis failed or was not indicated, and an overall symptomatic improvement was achieved in 95% of cases.In interstitial diseases, we highlight the article on the usefulness of BAL in the initial diagnosis of these diseases in a series of 562 patients studied over 14 years. The authors highlight the minimal invasiveness of the technique and its value which, when added to the radiological and clinical findings, enables these diseases to be managed without surgical biopsy in around 90% of cases.Finally, we highlight the works on lung transplant which analysed the value of interleukin-8 by BAL in the donor lung to detect sub-clinical involvement that could lead to a primary dysfunction of the lung graft, the risk factors associated to mortality in 92 lung transplant receivers due to emphysema and, lastly, the experience of the transplant in 15 patients with pulmonary arterial hypertension in an advanced functional class, with a peri-operative survival at 5 years of 40%. © 2010 Sociedad Española de Neumología y Cirugía Torácica. Source


Mendoza N.,University of Granada | Julia M.,Hospital Universitario La Fe Of Valencia | Galliano D.,Instituto Valenciano Of Infertilidad Ivi | Coronado P.,Complutense University of Madrid | And 10 more authors.
Maturitas | Year: 2015

Introduction: While we recognise that the term premature menopause is more accepted by most non-specialist health care providers and by the general population, 'primary ovarian insufficiency' (POI) iscurrently considered the most apposite term to explain the loss of ovarian function, because it betterexplains the variability of the clinical picture, does not specify definitive failure, and highlights the specificovarian source. Its pathogenesis involves a congenital reduction in the number of primordial follicles, poorfollicle recruitment, or accelerated follicular apoptosis. However, its cause is unknown in most cases.Aim: This guide analyses the factors associated with the diagnosis and treatment of POI and providesrecommendations on the most appropriate diagnostic and therapeutic measures for women under 40years of age who experience POI.Methodology: A panel of experts from various Spanish scientific societies related to POI (SpanishMenopause Society, Spanish Fertility Society, and Spanish Contraception Society) met to reach a con-sensus on these issues.Results: Hormonal therapy (HT) is considered the treatment of choice to alleviate the symptoms of hypoe-strogenism and to prevent long-term consequences. We suggest that HT should be continued until at leastage 51, the average age at natural menopause. The best treatment to achieve pregnancy is oocyte/embryodonation. If a patient is to undergo treatment that will reduce her fertility, she should be informed of thisissue and the available techniques to preserve ovarian function, mainly vitrification of oocytes. © 2014 Published by Elsevier Ireland Ltd. Source

Discover hidden collaborations